Randomized trial from China suggests better functional independence ...

Adjunctive treatment with intravenous (IV) tirofiban does not improve clinical outcomes in patients with large-vessel occlusion (LVO) stroke who undergo endovascular treatment (EVT) within 24 hours of ...

The stability and compatibility of tirofiban hydrochloride injection during simulated Y-site administration with various other drugs were studied. Tirofiban hydrochloride, dobutamine, epinephrine ...

PHOENIX -- For acute ischemic stroke patients without thrombolytic or thrombectomy options, tirofiban was better than aspirin alone, the TREND trial showed. In non-cardioembolic stroke, starting ...

The glycoprotein IIb/IIIa receptor inhibitor tirofiban (Aggrastat) generally failed to improve clinical outcomes for stroke patients undergoing endovascular therapy (EVT), according to the Chinese ...

The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not ...

Patients who undergo endovascular stroke therapy in combination with the glycoprotein IIb/IIIa inhibitor (GPI) tirofiban see a sharp increase in the risk of fatal intracerebral hemorrhage and have ...

PHOENIX, AZ—IV tirofiban lessens early neurological deterioration when given within 24 hours of symptom onset in patients with an acute noncardioembolic ischemic stroke who aren’t treated with IV ...

Learn everything you need to know about Tirofiban Hcl-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...

Please provide your email address to receive an email when new articles are posted on . In patients with acute ischemic stroke with large vessel occlusion who underwent endovascular therapy, tirofiban ...

In the setting of percutaneous coronary revascularization, agents in the class known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of death or nonfatal ...